Nick A Maskell
University of Bristol
Internal medicineRadiologySurgeryPathologyRandomized controlled trialIntensive care medicineMalignant pleural effusionPleural diseasePleurodesisMesotheliomaPneumothoraxThoracoscopyPleural effusionPopulationPleural infectionPleural fluidIn patientIncidence (epidemiology)Clinical trialMedicine
375Publications
51H-index
7,464Citations
Publications 376
Newest
#1Alex Dipper (UoB: University of Bristol)
#2Nick A Maskell (UoB: University of Bristol)H-Index: 51
Last. Anna C. Bibby (UoB: University of Bristol)H-Index: 11
view all 0 authors...
For a number of patients presenting with an undiagnosed pleural effusion, frailty, medical co-morbidity or personal choice may preclude the use of pleural biopsy, the gold standard investigation for diagnosis of malignant pleural mesothelioma (MPM). In this review article, we outline the most recent evidence on ancillary diagnostic tests which may be used to support a diagnosis of MPM where histological samples cannot be obtained or where results are non-diagnostic. Immunocytochemical markers, m...
Source
#1Tom Dudding (UoB: University of Bristol)H-Index: 11
#2Sadiyah Sheikh (UoB: University of Bristol)H-Index: 4
Last. Nick A Maskell (UoB: University of Bristol)H-Index: 51
view all 0 authors...
There remains uncertainty as to which dental procedures constitute aerosol generating procedures. We aimed to quantify aerosol concentration produced during different dental procedures. Where aerosol was detected, we assessed whether the aerosol size distribution from patient procedures was explained by the non-salivary contaminated instrument source, using phantom head controls. This study obtained ethical approval within the AERATOR grant. Patients were recruited consecutively, and written con...
Source
#1Rachelle Asciak (Churchill Hospital)H-Index: 7
#2Nikolaos I. Kanellakis (Churchill Hospital)H-Index: 12
Last. Stephen Montefort (Mater Dei Hospital)H-Index: 29
view all 0 authors...
BACKGROUND Most patients with malignant pleural mesothelioma (MPM) present with malignant pleural effusion (MPE). There is in vitro evidence that MPE may not be a simple bystander of malignancy, but potentially has biological properties improving cancer cell survival and promoting cancer progression. If this is the case, MPE management may need to shift from current symptomatic strategies to aggressive fluid removal to impact on survival. RESEARCH QUESTION Is there an association between pleural...
Source
#1S. Tsim (Glas.: University of Glasgow)H-Index: 5
#2Laura Alexander (Glas.: University of Glasgow)H-Index: 8
Last. Davand Sharma (Inverclyde Royal Hospital)
view all 0 authors...
Introduction null Malignant pleural mesothelioma (MPM) is difficult to diagnose. An accurate blood biomarker could prompt specialist referral or be deployed in future screening. In earlier retrospective studies, SOMAscan® proteomics and Fibulin-3 appeared highly accurate, but SOMAscan® has not been validated prospectively and subsequent Fibulin-3 data have been contradictory. null Methods null A multi-centre prospective observational study was performed in 22 centres, generating a large intentio...
Source
#1Anna BibbyH-Index: 3
Last. Nick A MaskellH-Index: 51
view all 0 authors...
Source
#1Maia Kavanagh Williamson (UoB: University of Bristol)H-Index: 7
#2Fergus Hamilton (UoB: University of Bristol)H-Index: 10
Last. Andrew D. DavidsonH-Index: 40
view all 19 authors...
There is widespread interest in the capacity for SARS-CoV-2 evolution in the face of selective pressures from host immunity, either naturally acquired post-exposure or from vaccine acquired immunity. Allied to this is the potential for long perm persistent infections within immune compromised individuals to allow a broader range of viral evolution in the face of sub-optimal immune driven selective pressure. Here we report on an immunocompromised individual who is hypogammaglobulinaemic and was p...
Source
Source
#1David T Arnold (North Bristol NHS Trust)H-Index: 15
#2Alice Milne (North Bristol NHS Trust)H-Index: 2
Last. Fergus Hamilton (North Bristol NHS Trust)H-Index: 10
view all 6 authors...
Source
#1David T Arnold (UoB: University of Bristol)H-Index: 15
#2Marie Attwood (North Bristol NHS Trust)H-Index: 5
Last. Fergus Hamilton (North Bristol NHS Trust)H-Index: 10
view all 12 authors...
INTRODUCTION COVID-19 has an unpredictable clinical course, so prognostic biomarkers would be invaluable when triaging patients on admission to hospital. Many biomarkers have been suggested using large observational datasets but sample timing is crucial to ensure prognostic relevance. The DISCOVER study prospectively recruited patients with COVID-19 admitted to a UK hospital and analysed a panel of putative prognostic biomarkers on the admission blood sample to identify markers of poor outcome. ...
1 CitationsSource
#1Nina Holling (University Hospitals Bristol NHS Foundation Trust)
#1Nina Holling (University Hospitals Bristol NHS Foundation Trust)
Last. Anna Bibby (North Bristol NHS Trust)H-Index: 3
view all 5 authors...
Background Malignant pleural effusions (MPE) often cause symptoms and guidelines recommend early definitive intervention. However, observational data suggest systemic anti-cancer treatment (SACT) may control MPE due to certain pharmacologically-sensitive tumours. Research question Is SACT associated with higher rates of MPE resolution in people with pharmacologically-sensitive tumours? Study design and methods This was a retrospective analysis of prospectively-collected data from an observationa...
Source